pentobarbital will reduce the extent or impact of cobimetinib by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Avoid coadministration. Powerful or moderate CYP3A inducers might minimize cobimetinib systemic exposure by >eighty% and decrease its efficacy.pentobarbital will lessen the extent or outcome of ixabepilone by in